OF PULMONARY EMBOLISM WITH SUBCUTANEOUS ENOXAPARIN
B. Mehić, Z. Dizdarević and H. Žutić.
of Lung Diseases, Clinical Centre University of Sarajevo,
Bosnia and Herzegovina
There are not so many articles about treatment of pulmonary embolism
(PE) with lowe molecular weight heparin (LMWH). Aim of Study:
Comparision of efficacy and safety treatment of PE with LMWH (enoxaparin),
and standard unfractionated heparin (UFH)on clinical sample. Patients
and Methods: We compared two groups pts with PE. In the groups
there was 38 pts (18 m and 20 f, age 58,2 12.4, 57.5% smokers
and 13.4% ex smokers) who treated with LMWH 1mg/kg/24h. In second
group there was 36 pts (15m and 21 f, age 59.1r 11.9, 54% smokers
and 11.5% ex smokers) who was treated with classic heparin 40000
IU/14h. Parametres for evaluation efficacy and safety of BE treatment
elaborated with calculating means and paired-samples t-test (Student
and Chi square test) Results: Analysis of risk factors which was
attend in both groups showed that there was not statisticalsignificant
differences (SSD) between pts of both groups (F2 =0.267, p=0.6).
The regression of clinical, radiological and significant signs
of PE was some faster in group which was treated with LMWH, but
there was not SSD between this group pts and group treated with
UFH (Student t-test = -0.96, p=0,23). Also, in anlysis of treatment
complication there was no SSD between two groups. Price of treatment
with LMWH was doubly reduced-clear cost benefit.
Conclusion: It looks that LMWH - enoxaparin making faster effects
in treatment PE with less complications, but in our study we are
not approved existence SSD in efficacy and safety in comparation
with gropup pts treated with UFH . But treatment with LMWH in
our situation is more than doubly cheaper than with UFH.